Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1268
Gene Symbol: CNR1
CNR1
0.340 Biomarker disease CTD_human Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. 9888857 1999
Entrez Id: 2166
Gene Symbol: FAAH
FAAH
0.320 Biomarker disease CTD_human Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. 19103437 2009
Entrez Id: 2166
Gene Symbol: FAAH
FAAH
0.320 GeneticVariation disease BEFREE Two single nucleotide polymorphisms (SNPs) in the CNR1 (rs2023239) and FAAH (rs324420) genes, associated previously with substance abuse and functional changes in cannabinoid regulation, were examined in a sample of daily marijuana smokers. 18705688 2008
Entrez Id: 2166
Gene Symbol: FAAH
FAAH
0.320 GeneticVariation disease BEFREE Owing to the importance of endocannabinoid system in addiction, the Pro129Thr polymorphism in the FAAH gene has reportedly been associated with substance abuse and dependence in a Caucasian population. 17621164 2007
Entrez Id: 4897
Gene Symbol: NRCAM
NRCAM
0.320 GeneticVariation disease BEFREE Polymorphisms in NrCAM have been reported to be associated with autism susceptibility and with substance abuse, implicating NrCAM in reward circuitry. 17106428 2006
Entrez Id: 4897
Gene Symbol: NRCAM
NRCAM
0.320 Biomarker disease CTD_human These observations support NrCAM as a positionally cloned and drug-regulated gene whose variants are likely to change expression and alter substance abuse vulnerabilities in human addictions and animal models of drug reward. 16123759 2006
Entrez Id: 4897
Gene Symbol: NRCAM
NRCAM
0.320 AlteredExpression disease BEFREE These observations support NrCAM as a positionally cloned and drug-regulated gene whose variants are likely to change expression and alter substance abuse vulnerabilities in human addictions and animal models of drug reward. 16123759 2006
Entrez Id: 2166
Gene Symbol: FAAH
FAAH
0.320 Biomarker disease CTD_human A missense mutation in human fatty acid amide hydrolase associated with problem drug use. 12060782 2002
Entrez Id: 2915
Gene Symbol: GRM5
GRM5
0.310 Biomarker disease BEFREE Preclinical data have shown that the excitatory metabotropic Gα<sub>q</sub>-coupled glutamate receptor, mGluR5, has a role in substance abuse and relapse. 30758331 2019
Entrez Id: 1012
Gene Symbol: CDH13
CDH13
0.310 Biomarker disease BEFREE No substantial signal was observed for either MAOA or CDH13 among non-violent offenders, indicating that findings were specific for violent offending, and not largely attributable to substance abuse or antisocial personality disorder. 25349169 2015
Entrez Id: 460
Gene Symbol: ASTN1
ASTN1
0.310 GeneticVariation disease BEFREE The ASTN1 gene is in this region, a gene previously reported to be associated with substance abuse, bipolar disorder and schizophrenia. 22488871 2012
Entrez Id: 460
Gene Symbol: ASTN1
ASTN1
0.310 Biomarker disease PSYGENET The ASTN1 gene is in this region, a gene previously reported to be associated with substance abuse, bipolar disorder and schizophrenia. 22488871 2012
Entrez Id: 4852
Gene Symbol: NPY
NPY
0.310 Biomarker disease BEFREE Genetic modulation of plasma NPY stress response is suppressed in substance abuse: association with clinical outcomes. 21917383 2012
Entrez Id: 1012
Gene Symbol: CDH13
CDH13
0.310 Biomarker disease CTD_human Genome wide association for addiction: replicated results and comparisons of two analytic approaches. 20098672 2010
Entrez Id: 2915
Gene Symbol: GRM5
GRM5
0.310 Biomarker disease CTD_human Genome wide association for addiction: replicated results and comparisons of two analytic approaches. 20098672 2010
Entrez Id: 4852
Gene Symbol: NPY
NPY
0.310 Biomarker disease CTD_human Neuropeptide Y augments cocaine self-administration and cocaine-induced hyperlocomotion in rats. 19063928 2009
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.310 GeneticVariation disease BEFREE We tested whether substance abuse disorder and suicidal behavior were associated with the CYP2D6 and CYP2C19 genotypes among patients with schizophrenia. 18520596 2008
Entrez Id: 1557
Gene Symbol: CYP2C19
CYP2C19
0.310 GeneticVariation disease BEFREE We tested whether substance abuse disorder and suicidal behavior were associated with the CYP2D6 and CYP2C19 genotypes among patients with schizophrenia. 18520596 2008
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.310 Biomarker disease CTD_human Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. 17089107 2006
Entrez Id: 5340
Gene Symbol: PLG
PLG
0.310 Biomarker disease BEFREE This study suggests that t-PA/plasminogen system is unlikely to be a major contributor to the substance abuse liability and/or the development of MAP psychosis. 15542697 2004
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.300 Biomarker disease CTD_human Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. 27192616 2016
Entrez Id: 2272
Gene Symbol: FHIT
FHIT
0.300 Biomarker disease CTD_human Genome wide association for addiction: replicated results and comparisons of two analytic approaches. 20098672 2010
Entrez Id: 114788
Gene Symbol: CSMD3
CSMD3
0.300 Biomarker disease CTD_human Genome wide association for addiction: replicated results and comparisons of two analytic approaches. 20098672 2010
Entrez Id: 64131
Gene Symbol: XYLT1
XYLT1
0.300 Biomarker disease CTD_human Genome wide association for addiction: replicated results and comparisons of two analytic approaches. 20098672 2010
Entrez Id: 84247
Gene Symbol: RTL6
RTL6
0.300 Biomarker disease CTD_human Genome wide association for addiction: replicated results and comparisons of two analytic approaches. 20098672 2010